ARTSS-2: A pilot, phase IIb, randomised, multi-center trial of Argatroban in combination with recombinant tissue plasminogen activator for acute stroke

Trial Profile

ARTSS-2: A pilot, phase IIb, randomised, multi-center trial of Argatroban in combination with recombinant tissue plasminogen activator for acute stroke

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Argatroban (Primary) ; Alteplase
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARTSS-2
  • Most Recent Events

    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
    • 19 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by results presented at the 41st International Stroke Conference
    • 19 Feb 2016 Results presented at the 41st International Stroke Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top